Detalhe da pesquisa
1.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30110579
2.
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Br J Cancer
; 123(9): 1360-1369, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32741975
3.
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
Future Oncol
; 15(19): 2211-2225, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074641
4.
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Blood
; 127(13): 1656-65, 2016 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825712
5.
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Biol Blood Marrow Transplant
; 23(6): 997-1004, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285079
6.
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Br J Haematol
; 178(1): 112-118, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28444784
7.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat
; 165(2): 329-341, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28612225
8.
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 16(15): 1556-1568, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26482278
9.
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Lancet Oncol
; 14(12): 1216-25, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24095299
10.
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat
; 166(1): 327-328, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28884461
11.
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
Invest New Drugs
; 30(4): 1676-83, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21826439
12.
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Invest New Drugs
; 30(6): 2294-302, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22072399
13.
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
JAMA Oncol
; 8(7): 1047-1052, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552364
14.
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Clin Cancer Res
; 28(10): 2020-2029, 2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35165101
15.
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072.
Clin Pharmacol Ther
; 109(2): 383-393, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32681519
16.
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Clin Cancer Res
; 27(16): 4521-4530, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083236
17.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301809
18.
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Cancer Discov
; 10(8): 1158-1173, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32439653
19.
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Clin Cancer Res
; 25(9): 2717-2724, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563931
20.
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Clin Cancer Res
; 24(14): 3348-3357, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29618616